evaluate novo nordisk on glp-1 agonists Bolsters Portfolio With OZEMPIC's New Approval Novo Nordisk vs Eli Lilly:
Description
A systematic literature review and network metaanalysis comparing onceweekly semaglutide with other GLP1 receptor agonists in patients with type 2 diabetes previously receiving 12 oral antidiabetic drugs
GLP-1 receptors are expressed in the atrial myocardium and the sinoatrial node
Deganutti, G
Lee SH, Ko HM, Jee W, Kim H, Chung WS, Jang HJ
